[{"address1": "1 Ashley Road", "address2": "3rd Floor", "city": "Altrincham", "zip": "WA14 2DT", "country": "United Kingdom", "website": "https://www.centessa.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.", "fullTimeEmployees": 77, "maxAge": 86400, "priceHint": 2, "previousClose": 8.86, "open": 9.0, "dayLow": 8.75, "dayHigh": 9.46, "regularMarketPreviousClose": 8.86, "regularMarketOpen": 9.0, "regularMarketDayLow": 8.75, "regularMarketDayHigh": 9.46, "beta": 1.399, "forwardPE": -5.229885, "volume": 482399, "regularMarketVolume": 482399, "averageVolume": 216808, "averageVolume10days": 278450, "averageDailyVolume10Day": 278450, "bid": 9.06, "ask": 9.14, "bidSize": 100, "askSize": 100, "marketCap": 1028700416, "fiftyTwoWeekLow": 5.15, "fiftyTwoWeekHigh": 12.45, "priceToSalesTrailing12Months": 150.1095, "fiftyDayAverage": 9.3041, "twoHundredDayAverage": 8.349125, "currency": "USD", "enterpriseValue": 884597632, "floatShares": 71076568, "sharesOutstanding": 113044000, "sharesShort": 1763646, "sharesShortPriorMonth": 1284974, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.0156, "heldPercentInsiders": 0.02049, "heldPercentInstitutions": 0.77359, "shortRatio": 7.18, "shortPercentOfFloat": 0.0199, "impliedSharesOutstanding": 113044000, "bookValue": 2.141, "priceToBook": 4.2503505, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -138416992, "trailingEps": -1.42, "forwardEps": -1.74, "enterpriseToRevenue": 129.082, "enterpriseToEbitda": -5.594, "52WeekChange": 0.31884062, "SandP52WeekChange": 0.26238096, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "CNTA", "underlyingSymbol": "CNTA", "shortName": "Centessa Pharmaceuticals plc", "longName": "Centessa Pharmaceuticals plc", "firstTradeDateEpochUtc": 1622208600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "9f3bdf1d-ddc8-3bbd-88f7-8fed1cc82ba8", "messageBoardId": "finmb_704505677", "gmtOffSetMilliseconds": -14400000, "currentPrice": 9.1, "targetHighPrice": 20.0, "targetLowPrice": 11.0, "targetMeanPrice": 14.2, "targetMedianPrice": 14.0, "recommendationMean": 1.6, "recommendationKey": "buy", "numberOfAnalystOpinions": 5, "totalCash": 230176992, "totalCashPerShare": 2.036, "ebitda": -158136992, "totalDebt": 86072000, "quickRatio": 9.745, "currentRatio": 10.369, "totalRevenue": 6853000, "debtToEquity": 40.003, "revenuePerShare": 0.07, "returnOnAssets": -0.27064, "returnOnEquity": -0.54449004, "freeCashflow": -92709248, "operatingCashflow": -149790000, "grossMargins": 1.0, "operatingMargins": -23.127972, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]